# Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

> **NCT02579382** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 192 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** TDF
- **DRUG:** Vesatolimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02579382
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-10
- **Primary completion:** 2017-01-16
- **Final completion:** 2019-05-03
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2020-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02579382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02579382, "Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02579382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*